Researchers found that over 80% of Americans meet the criteria for SGLT2 inhibitors or GLP-1 receptor agonists. However, only about 10% of those who used the medication between 2017 and 2020.
“It’s important for primary care providers to be aware that many of their patients with type 2 diabetes may qualify for these medications,” Shichao Tang, PhD, of the CDC’s Division of Diabetes Translation, told Healio.
The American Diabetes Association and the European Association for the Study of Diabetes published a consensus report in 2022 recommending the use of GLP-1.
